Kymera's KT-485 Enters Phase 1 Trial, Triggers $20M Sanofi Milestone with $975M Potential
KYMR has more than doubled off its 52-week low of $36.65.
Summary
Kymera Therapeutics announced the dosing of the first participant in its Phase 1 trial for KT-485, an oral IRAK4 degrader. This significant pipeline advancement triggered a $20 million milestone payment from Sanofi, with the potential for up to $975 million in additional milestones. This follows recent positive news including strong Q1 results and promising preclinical data for other candidates. Advancing KT-485 into human trials is a key de-risking event for the program and provides substantial non-dilutive capital, validating the Sanofi collaboration. Future updates on the Phase 1 trial will be important.
At the time of this announcement, KYMR was trading at $73.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $36.65 to $103.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.